PURPOSE: To develop and validate a method to prepare clarithromycin (CLM) microcapsules to mask the bitter taste and provide effective treatment, and evaluate the quality of microcapsules in detail, especially the in vitro and in vivo pharmacokinetics behavior.
INTRODUCTION
A s every pharmacist knows, many pharmaceutical drugs have an unpleasant taste, often very bitter. Th e major consequence of the bitter taste is to restrict greatly the further development of oral preparations and clinical applications of these drugs. Along with the continuing improvement in the social standard of living, it is no longer acceptable for useful medicines to taste bitter. People wish to take eff ective drugs that have a nice taste and can be administered easily. Accordingly, it is important to mask the unpalatable taste of a drug in order to improve the product quality [1] . In order to achieve more pleasant dosage forms, various masking techniques have been described and microspheres techniques was one of the most popular method.
Microspheres are one of the multiparticulate delivery systems and are prepared to obtain prolonged or controlled drug delivery, to improve bioavailability or stability and to target drug to specific sites [2] . Microspheres can also off er advantages like limiting fluctuation within therapeutic range, reducing side eff ects, decreasing dosing frequency and improving patient compliance [3] . Various technologies have been proposed for fabricating microspheres, which include solvent evaporation [4, 5] , phase-separation [6] , and spray-drying [7, 8] .
Clarithromycin (6-0-methyl-erythromycin A) is a 14-membered macrolide antimicrobial agent widely used for treatment of infections such as respiratory infection, skin soft tissue infection, choamydiae infection and helicobacter pylori infection and so on [9, 10] . It is also clinically active against bacteria responsible for exacerbations of chronic bronchitis and the atypical pathogens that cause respiratory tract infections [11] [12] [13] . CLM was stable in the gastric acid and well absorbed, but it has a very bitter taste, this make it inconvenient when take orally.
In the production, it is hard to mask the bitter taste of CLM by simply adding correctives to the dry suspension and granules. Although it is able to mask the bitter by fl uidized bed coating technique, the equipments have to consume considerable money and the operation is complicated. So it is necessary to search for a new way to prepare CLM dosage forms for masking the bitter. In this paper, Th e CLM microcapsules were prepared with ethyl cellulose (EC) as matrix material by an emulsion solvent diff usion method. Th e quality evaluation of prepared microcapsules was qualifi ed, and mixed with other adjuvant to prepare CLM dry suspension, and its pharmacokinetics in vivo was investigated with CLM conventional tablets as reference.
MATERIALS, INSTRUMENTATION AND METHODS

Materials
Clarithromycin crude drug was purchased from Vitalpharms Company Ltd. (Zhuhai, China). CLM conventional tablet was kindly purchased from Shanghai Abbott Laboratories Ltd. (Shanghai, China). Commercial CLM granules were purchased from Yongan pharmaceutical Ltd. (Yunnan, China). Reference standard of CLM was provided by the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). CLM microcapsules were self-made. EC (viscosity 20 cP) was purchased from Colorcon Ltd. (Shanghai, China). Ethyl acetate was obtained from Tianjin Xintong fi ne chemicals Ltd. (Tianjin, China). Poloxamer 188 and sodium carboxymethyl cellulose (CMC-Na, viscosity 200~500 cP, MW 600~800) were purchased from Xietai chemical agent Ltd. All other reagents and chemicals were of analytical grade and were obtained from the manufacturers.
Instrumentation
DF-101S constant temperature heating magnetic stirrer (Yuhua Instrument CO., LTD., Gongyi, China); FA-1104N electronic analytical balance (Shanghai minqiao precise scientifi c instrument limited company, Shanghai, China), Electron microscope (Chongqing optical instrument factory, Chongqing, China); AccuSizer780/DPS dry power particle size analysator (PSS LTD, American); D-800L intelligence drug dissolution tester (Tianjin university radio company, Tianjin, China); P3000 analysis mode HPLC (including P3000 analysis mode pump, UV3000 ultraviolet detector, Beijing Chuangxin tongheng technology limited company, Beijing, China), JHH-150SD drug stability test apparatus (Yongsheng laboratory apparatus company, Chongqing, China).
The preparation of CLM microcapsules
Th e microcapsules were prepared by emulsion solvent diff usion method [14] . Briefly, the preparation involved fi ve steps: 
Particle size and morphology evaluation
Optical microscope was used to evaluate both the morphology and surface characteristics of the microcapsules. Particle size of the CLM microcapsules was determined by an AccuSizer780/DPS dry power particle size analysator before dispersing the microcapsules in deionized water.
Drug loading rate and entrapment rate
Validation of the optimized HPLC method was carried out with respect to the following parameters.
Chromatographic conditions
Th e HPLC separation was performed using a KromasilC 18 (250 mm×4.6 mm, 5 μm). Th e mobile phase, consisting of potassium dihydrogen phosphate (KDP, 0.067 mol/l) -acetonitrile (6:4), was delivered at a fl ow-rate of 1.0 ml/min; Detection was set at 210 nm and the column temperature was maintained at 45°C. Injections were carried out using a 20 μl loop.
Linearity and range
Standard solution of CLM was prepared to a concentration of 3 mg/ml in a volumetric fl ask of 50 ml. Th en dilute to 0.060 mg/ml, 0.12 mg/ml, 0.24 mg/ ml, 0.36 mg/ml, 0.48 mg/ml, 0.60 mg/ml and 0.72 mg/ml, respectively. Inject the sample of 20 μl, memorize the chromatogram. Th e diff erent peak area of diff erent concentration was drawn with the regression equation.
Precision
Inject the control sample in 5 times repeatly, and memorize the peak areas, and then calculate the RSD.
Reproducibility
Determine the same sample 5 times according to the method of 2.5.2 of this literature, and then calculate the RSD.
Sample analysis
Comminute CLM microcapsules and weight 40 mg (containing CLM 17.5 mg) of fi ne powders accurately, dissolve to a volumetric fl ask of 50 ml with the mobile phase using the ultrasound, then dilute to the scale, shake and fi lter. Take 20 μl of fi lter liquor accurately, inject and calculate the contents.
Calculate the entrapment rate and drug loading rate with following formula [15] :
( ) = × weight of the drug loaded in the microcapsules Drug loading rate 100% the total weight of the microspheres = × actual drug content Entrapment rate 100% theoretical drug content 2.6. In vitro release study CLM microcapsules (1120 mg equivalent to drug 500 mg) and crude drug (500 mg) were incubated in 900 ml of acetate buff er (pH 5.0) at 37±1°C under magnetic stirring at 100 r•min-1. Th en it was determined according to China Pharmacopoeia 2005. At fi xed time intervals an aliquot of suspension (5 ml) was withdrawn and fi ltered. Th en the same volume of release medium is added. Take the fi lter liquor and determine according to the part of 2.5.2, then calculate accumulative release rate. Th en the regression equations of release curves of CLM microcapsules are made.
Stability test
A short-term stability study was carried out at 40 °C, RH75% for 3 months.
Sensory Test
Based on clinical usage, dosage and specifi cation of preparation, we defi nitely determine the prescription of dry suspension 250 mg per pouch. Take 11.2 g CLM microcapsules (containing CLM 5.0 g), 66.5 g sucrose, 25.0 g CMC-Na, 0.50 g sodium citrate, 0.50 g aspartame and mix together sufficiently. Pack 20 pouches. Th e prescription of dry suspension is 250 mg per pouch.
A single randomly study was designed for the sensory test in the buccal cavity. 18 volunteers participated in the sensory test. Th e 18 volunteers were divided into 2 sets blindly. Each set was 9 volunteers. Set 1 was administered commercial CLM dry suspension, and set 2 was administered self-made CLM dry suspension. One pouch of dry suspension was dispersed in 20 ml of water for 10 min. Immediately after preparation, each volunteer held about 1 ml of the dispersion in the mouth for 30 s. After expectoration, bitterness was evaluated.
Pharmacokinetics 2.9.1. Method validation
A microbiological cup-plate method was used in this part and the micrococcus luteus [CMCC(B)28001] was used as appreciation strain. To evaluate linearity, plasma calibration curves were prepared and assayed in triplicate on three consecutive validation days. Accuracy and precision were also assessed by determining QC samples at three concentration levels on the three diff erent validation days. Th e accuracy was expressed by RE and the precision by RSD. Th e extraction recoveries of CLM at three QC levels were determined.
Application to a clinical pharmacokinetic study
Th e bioavailability study was in accordance with GCP/GLP standards. Th e protocol was approved by an ethics committee on bioavailability studies. Th e study was conducted on 12 healthy volunteers. Each volunteer was fully informed both in writing and verbally about the aim of the study. Th e 12 volunteers were divided into 2 sets randomly. Each set was 6 volunteers. Set 1 was administered one pouch of Self-made CLM dry suspension containing 250 mg CLM, and set 2 was administered one CLM conventional tablet containing 250 mg CLM after an overnight fast. Blood samples of 4 ml were collected just before and at 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 h after drug administration. Th e samples were placed in vacutainers (containing sodium heparin). Following centrifugation, the plasma samples were immediately frozen and stored (-18°C to -20°C) until assayed.
Th e pharmacokinetic parameters were calculated by non-compartmental methods. Th e AUC 0-t was calculated using the trapezoidal method. C max and T max were obtained directly from the individual plasma concentration time profi les, k e was obtained as the slope of the linear regression of the log-transformed concentration versus time data in the terminal portion of the curve and t 1/2 was calculated as 0.693/k e
RESULTS AND DISCUSSION
Particle size and morphology evaluation
Under the optical microscope, the appearance of microcapsules was accord with requirement. Appearance of microcapsules under optical microscope was shown in Figure 1 . Th e mean diameter of microcapsules was shown in Table 1 . Th e micrographs show regular spherical shapes. It is apparent that the microspheres appear a smooth surface, welldistributed (mean diameter was 35.3μm) with no accretion among the microspheres.
Drug loading rate and entrapment rate 3.2.1. Linearity and range
Th e diff erent peak area of diff erent concentration was drawn with the regression equation: A = 11766+3003.2C, R=0.9999. With the result, the peak area and concentration was showed a fi ne linearity with a concentration range of 0.060-0.72 mg/ml. 
Precision
Inject the control sample in 5 times repeatly, and memorize the peak areas, the RSD was 0.50%.
Reproducibility
Determine the same sample 5 times according to the method of 2.5.2 of this literature, the RSD was 0.31%.
Sample analysis
Th ree batches of microspheres were prepared based on the formulation, according to the method introduced above; the entrapment rate and drug loading rate were also shown in Table 1 . Th e results indicated a high quality of the microspheres with entrapment rate and drug loading rate were (88.90±1.38)% and (46.34±0.82)% respectively.
In vitro release study
Th e dissolution rate of pure drug and the drug release rate from 3 batches of CLM microcapsules (batch number: 20070910, 20070915, 20070923) in acetate buff er solution were studied. Th e accumulated release curve was obtained in Figure 2 . Th e result shows that compared to the pure drug, the self-made CLM microcapsules could sustain-release in vitro and the release rate was coincident among diff erent batches. Th e rate of accumulated release is 75% on 6 h, meeting the design request.
Regression equations and correlation coeffi cients of diff erent mathematical models of release curves of CLM microcapsules in vitro were showed in Table 2 . According to the result, it was found that the dissolution rate of CLM microcapsules conformed to Higuchi equation and Peppas equation. Th e drug releasing mechanism of the preparation was chiefl y characterized by drug diff usion including bulk erosion non-Fickian process.
Stability test
A short-term stability study was carried out at 40°C, RH 75% for 3 mouths and the results are shown in Table 3 .
From Table 3 , we can fi nd that the appearance under microscope, drug loading rate and accumulative release rate were no signifi cant changes. So it can be concluded that CLM microcapsules are stable for a period of 3 months under the accelerated test.
Sensory Test
Th e degree of bitterness was classifi ed using 3 grades, corresponding to increasing bitterness, and a comparison of bitterness among samples was performed based on the total number of persons who selected "bitter" and "slightly bitter". Th e ranking scheme used is shown in Table 4 . Th e threshold of bitterness of Self-made CLM dry suspension was determined as the point at which half of the volunteers described the taste as bitter or slightly bitter. Th e results showed that the self-made CLM dry suspension suffi ciently alleviate the bitterness of commercial CLM dry suspension (Table 4 ).Th is indicated that CLM was entrapment in the microcapsules; the bitter taste was masked effi ciently in our research.
A research performed by Gao et al (1) was also for roxithromycin taste masking by microcapsule. Both as macrolide antibiotics, chemical structure and hydrophilicity (solubility) of CLM and roxithromycin are similar, so the authors focus on the diff erence of materials and methods in two papers.
In the research of Gao, Eudragit S100 was used as polymers material, mixture of ethanol, acetone and dichloromethane were used as solvents, distilled water was used as external phase, Ratio of drug and Eudragit S100 was 1:1. Microspheres of roxithromycin were prepared by the emulsion solvent diff usion method to mask the bitter taste.
In our study microcapsule were also prepared by the emulsion solvent diff usion method to mask the bitter taste, drug to polymers material (EC) was also 1:1, as we all know, the bitterness of macrolide antibiotics was clarithrmycin > Azithromycin > Roxithromycin. So a deeper study was done. We investigate microcapsule using roxithromycin as a model drug using our materials and method, drug to EC was maintained at 3:1 and dry suspension was also made in the study. Th e result of sensory test showed that this roxithromycin formulation was not bitter. Th is indicated that the microcapsule prepared by our method, drug to polymers material EC can reach 3:1, the drug loading is higher than that by Gao's (1:1).
In our study, the authors used ethyl acetate as solvent; the toxicity of ethyl acetate is smaller than that of acetone and dichloromethane reported by Gao's.
Moreover, distilled water which presatured by ethyl acetate was used as external phase in our study, and distilled water was used by Gao. We also investigate microcapsule using distilled water as external phase during our study, but no microcapsule was obtained. Th is was because acetic ether is soluble in water, when oil phase was added, acetic ether in the oil phase can disperse to aqueous phase quickly, which made the EC fl oated in the solution to form a fi lm, microcapsule can not obtained in this case. Distilled water presatured by ethyl acetate can avoid this by decreasing the disperse rate of acetic ether in aqueous phase. Th e morphology of microcapsule was integrity and yield was high. 
Precision and accuracy
Precision and accuracy were assessed by determining quality control (QC) samples at 0.02, 0.50 and 4.0 μg•mL -1 on three diff erent validation days. Th e intra-run and inter-run precisions ranged from 2.7 % to 3.3 % and from 1.2 % to 1.5 % for each QC level, respectively. Th e accuracy was within 0.7%. Th e results, calculated using one-way ANOVA, indicated that the values were within the acceptable range and the method was accurate and precise.
Method selection
Th e maximum absorption wavelength of CLM was 210nm, so the specifi city of HPLC-UV method for the determination of biological samples was not suitable. Some method including HPLC with electrochemical detection [16] or amperometric detection [17] , LC-MS/MS [18] , have been published 
Set 1
No bitter
Bitter for the determination of in plasma samples. But these methods need a liquid-liquid extraction or solid phase extraction from the plasma, this made the operation so complicated and the instrument needed was expensive; so in this article, a microbiological method was used for the determination of CLM in human plasma. From the result of linearity, lower limit of quantifi cation, precision and accuracy, we know that this method was accurate, convenient and sensitive for the estimation of pharmacokinetic parameter relative bioavailability of CLM dry suspension.
Application to a clinical pharmacokinetic study
Th is method was adopted to determine the plasma concentration of Self-made CLM dry suspension and conventional tablet after a single oral administration of 250 mg CLM to 12 male volunteers. Mean plasma concentration-time profi les of Self-made CLM dry suspension and conventional tablet are depicted in Figure 3 . Pharmacokinetic parameters are depicted in Table 5 . Th e pharmacokinetic parameters of dry suspensions and conventional tablets were as following. C max ; T max were 3.51±0.54 and 2.01±0.42 h; AUC were 7.65±2.54 and 7.12±2.10 μg•h•ml -1 , T 1/2 were 3.54±1.32 and 4.21±1.86, respectively. Cmax and AUC were not signifi cantly diff erent, but T max was signifi cantly different. Th is indicated that the self-made CLM dry suspension containing microcapsules did not decrease the bioavailability and had better eff ect for delaying the release behavior signifi cantly in healthy volunteers.
CONCLUSION
Th e rate of CLM release from these microcapsules into phosphate buff er appeared to be dependant upon a number of factors including diff erences in drug loading rate, drug solubility, microsphere surface area, surface morphology, hydrophobic nature and crystallinity of the polymer. Th e rate of polymer solidifi cation appeared to be the main factor that determined the Drug loading rate.
According to the Optical microscope analysis, the prepared CLM microcapsules show a spherical morphology, a smooth surface, and no concretion. Th e dry suspensions of CLM have better eff ect for avoiding bitter taste and delaying drug release.
Th e established HPLC method is simple, rapid, suitable, sensitive, cost less and non-interference for the determination of plasma concentration of CLM and the study of pharmacokinetics.
